Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Nemtabrutinib (MK-1026) versus investigator's choice of ibrutinib or acalabrutinib in first-line chronic lymphocytic leukemia/small lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (Calquence) (acalabrutinib)
• Ibrutinib (Imbruvica) (Ibrutinib)
• Nemtabrutinib (MK-1026) (nemtabrutinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: RECRUITING